Children's Idiopathic Thrombocytopenic Purpura (ITP) is the most common hemorrhagic disease in children, characterized by a decrease in the number of platelets in the blood with symptoms of easy bruising, nosebleeds, bleeding gums, and internal bleeding. ITP in children could be acute in less than 6 months, or chronic longer than 6 months. The aim of treatments for Children’s ITP is to balance the quality of life and drug efficacy, with treatment options with a variety of medications or surgery in some severe cases. The use of thrombopoietin receptor agonists (TPO-RAs) in treatment for children’s ITP has been gradually improved recently. TRAs is becoming the first-line of the treatment for children’s ITP from the third-line to the second-line, but there are still many clinical problems about how to well use TRAs to manage children's ITP.
For this Article Collection, the goal is to solicit submission of any articles to showcase the results and perspectives of TPO-RAs related treatment in children thrombocytopenia (especially in children ITP) including but not limited to the efficacy, safety, PK/PD, switching, reduction/withdrawing, and pharmacoeconomics:
- Effectiveness of TPO-RAs in children’s ITP
- Safety of TPO-RAs in children’s ITP
- PK/PD of TPO-RAs in children’s ITP: initial dosage, titration dosage, correlation between dose and efficacy/safety, and dose effect relationship
- Effects of TPO-RAs for ITP in children with different ages
- Effects of TPO-RAs in children’s ITP at different disease stages (NITP, PITP, CITP)
- Pharmacoeconomic data of TPO-RAs of ITP in children: quality of life (KIT assessment) and treatment cost/quality of life
Annals of Medicine accepts the following types of articles:
- Research Articles
- Review Articles
- Clinical Trials
- Protocols
- Case Series
- Commentaries
- Letter To The Editor
When submitting your article, please select the section, ‘Hematology’, and the Special Issue, ‘Management of Bleeding and Thrombosis in Children: TRAs Treatments in Children’s Thrombocytopenia’ from the drop-down menu on the submission system.
Annals of Medicine is an online, open access, international journal publishing across all areas of medicine and is part of our Elevate Series. This means that you will receive a concierge-level publishing experience, including dedicated support from our expert in-house Editorial team, with guaranteed response times of within 48 hours, an initial decision on whether your article will be peer reviewed within 5 working days, and a first decision on your research within an average of 22 working days.
